Patient Reported Outcomes Show Improved Symptoms With Zongertinib for HER2-Mutated Non-Small Cell Lung Cancer

Zongertinib (Boehringer Ingelheim) yielded clinically meaningful improvements in disease-related symptoms, physical functioning, and symptomatic adverse events (AEs) in patients with human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC). The patient-reported outcomes (PROs) from the Beamion LUNG-1 trial (NCT04886804) will be presented at the 2025 ASCO Annual Meeting in Chicago, Illinois.¹